First Time Loading...

ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 3.09 USD +1.31% Market Closed
Updated: Sep 30, 2023

Intrinsic Value

Intrinsic Value History
ESSA Pharma Inc

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access ESSA Pharma Inc's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Example
Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Example
Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Example
Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis

Financials

Balance Sheet Decomposition
ESSA Pharma Inc

Current Assets 153m
Cash & Short-Term Investments 152m
Receivables 133k
Other Current Assets 688k
Non-Current Assets 360k
PP&E 95.2k
Other Non-Current Assets 265k
Current Liabilities 3.4m
Accounts Payable 2.1m
Accrued Liabilities 1.4m
Efficiency
Fundamental Scores

EPIX Profitability Score
Profitability Due Diligence

ESSA Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

36/100
Profitability
Score

ESSA Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

EPIX Solvency Score
Solvency Due Diligence

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EPIX Price Targets Summary
ESSA Pharma Inc

Wall Street analysts forecast EPIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EPIX is 19.79 USD with a low forecast of 15.15 USD and a high forecast of 28.35 USD.

Lowest
Price Target
15.15 USD
390% Upside
Average
Price Target
19.79 USD
540% Upside
Highest
Price Target
28.35 USD
817% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EPIX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EPIX Return Decomposition
Main factors of price return

What is price return decomposition?

EPIX Price
ESSA Pharma Inc

1M 1M
+2%
6M 6M
+5%
1Y 1Y
+70%
3Y 3Y
-55%
5Y 5Y
-2%
10Y 10Y
-97%
Annual Price Range
3.09
52w Low
1.5
52w High
4.82
Price Metrics
Average Annual Return 66.75%
Standard Deviation of Annual Returns 89.24%
Max Drawdown -96%
Shares Statistics
Market Capitalization 136m USD
Shares Outstanding 44 092 374
Percentage of Shares Shorted 0.11%

Company Profile

ESSA Pharma Inc Logo
ESSA Pharma Inc

Country

Canada

Industry

Biotechnology

Market Cap

136m USD

Dividend Yield

0%

Description

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

Contact

BRITISH COLUMBIA
Vancouver
Suite 2600, 595 Burrard Street
+17783310962.0
https://www.essapharma.com/

IPO

-

Employees

30

Officers

Pres, CEO & Director
Dr. David Ross Parkinson M.D.
Chief Financial Officer
Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA
Exec. VP & COO
Mr. Peter A. Virsik M.B.A., M.S.
Chief Medical Officer
Dr. Alessandra Cesano M.D., Ph.D.
Exec.
Nkengyal Barber

See Also

Other Stocks